Breast cancer staging in a single session: Whole-body PET/CT mammography

Journal of Nuclear Medicine

Volumn 49, Issue 8, 2008, Pages 1215-1222

  Heusner, Till A ^a   Kuemmel, Sherko ^a   Umutlu, Lale ^a   Koeninger, Angela ^a   Freudenberg, Lutz S ^a   Hauth, Elke A M ^a   Kimmig, Klaus R ^a   Forsting, Michael ^a   Bockisch, Andreas ^a   Antoch, Gerald ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Breast cancer; Mammography; Oncology; PET CT; Whole body imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST METASTASIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISTANT METASTASIS; ECHOMAMMOGRAPHY; FEMALE; FISHER EXACT TEST; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MEDIASTINUM METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROPERITONEAL CANCER; SENTINEL LYMPH NODE BIOPSY; TISSUE SECTION; UTERINE CERVIX CANCER; WHOLE BODY CT;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 48749083122     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.052050     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56:168-183.
3. Thurlimann B, Muller A, Senn HJ. Management of primary breast cancer: an update. Onkologie. 2004;27:175-179.
4. Agnese DM. Advances in breast imaging. Surg Technol Int. 2005;14:51-56.
5. Scheidhauer K, Walter C, Seemann MD. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S70-S79.
6. Rausch DR, Hendrick RE. How to optimize clinical breast MR imaging practices and techniques on your 1.5-T system. Radiographics. 2006;26:1469-1484.
7. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233:830-849.
8. Winnekendonk G, Krug B, Warm M, Gohring UJ, Mallmann P, Lackner K. Rofo. 2004;176:688-693.
9. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290:3199-3206.
10. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007;48(suppl 1):78S-88S.
11. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360-385.
12. Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S135-S142.
13. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006;33:254-262.
14. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer. 2006;107:2545-2551.
15. 18F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma. Breast J. 2007;13:424-425.
16. Heusner T, Freudenberg LS, Kuehl H, et al. Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol. May 28, 2008 [Epub ahead of print.]
17. Kreienberg R, Kopp I, Lorenz W, et al. Diagnostik, therapie und nachsorge des mammakarzinoms der frau. In: Leitlinien der Deutschen Krebsgesellschaft. Frankfurt/Main, Germany: Informationszentrum für Standards in der Onkologie; 2004:2-172.
18. Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology. 2004;230:879-885.
19. Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003;30:588-596.
20. 18F-FDG PET. J Nucl Med. 2005;46:1819-1824.
21. Tardivon AA, Athanasiou A, Thibault F, El Khoury C. Breast imaging and reporting data system (BIRADS): magnetic resonance imaging. Eur J Radiol. 2007;61:212-215.
22. Degani H, Gusis V, Weinstein D, Fields S, Strano S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med. 1997;3:780-782.
23. Furman-Haran E, Grobgeld D, Margalit R, Degani H. Response of MCF7 human breast cancer to tamoxifen: evaluation by the three-time-point, contrast-enhanced magnetic resonance imaging method. Clin Cancer Res. 1998;4:2299-2304.
24. Hauth EA, Jaeger H, Maderwald S, et al. Evaluation of quantitative parametric analysis for characterization of breast lesions in contrast-enhanced MR mammography. Eur Radiol. 2006;16:2834-2841.
25. Hauth EA, Stockamp C, Maderwald S, et al. Evaluation of the three-time-point method for diagnosis of breast lesions in contrast-enhanced MR mammography. Clin Imaging. 2006;30:160-165.
26. Beggs AD, Hain SF, Curran KM, O'Doherty MJ. FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging. 2002;29:542-546.
27. 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer [in Chinese]. Ai Zheng. 2007;26:900-904.
28. Reddy DH, Mendelson EB. Incorporating new imaging models in breast cancer management. Curr Treat Options Oncol. 2005;6:135-145.
29. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495-3502.
30. Boone JM, Kwan AL, Yang K, Burkett GW, Lindfors KK, Nelson TR. Computed tomography for imaging the breast. J Mammary Gland Biol Neoplasia. 2006;11:103-111.
31. 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440-1446.
32. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology. 1999;213:881-888.
33. Malich A, Fischer DR, Wurdinger S, et al. Potential MRI interpretation model: differentiation of benign from malignant breast masses. AJR. 2005;185:964-970.
34. Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005;103:1898-1905.
35. Friedrich M. MRI of the breast: state of the art. Eur Radiol. 1998;8:707-725.
36. Avril N, Schelling M, Dose J, Weber WA, Schwaiger M. Utility of PET in breast cancer. Clin Positron Imaging. 1999;2:261-271.
37. Wang YYJ, Liu J, Tong Z, Sun X, Yang G. PET-CT in the diagnosis of both primary breast cancer and axillary lymph node metastasis: initial experience. Int J Radiat Oncol Biol Phys. 2003;57:362-363.
38. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008;109:417-426.